Galvus OD 100mg Tablet MR contains Vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. By selectively inhibiting the DPP-4 enzyme, Vildagliptin enhances the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control without causing significant hypoglycemia. This modified-release formulation allows for once-daily dosing, improving patient compliance and maintaining stable plasma drug concentrations throughout the day. Galvus OD 100mg is typically prescribed as monotherapy or in combination with other antidiabetic agents such as metformin or insulin when diet and exercise alone do not provide adequate glycemic control. It is particularly beneficial for patients who require effective blood sugar management with a low risk of weight gain or hypoglycemia. Patients should follow their healthcare provider’s instructions regarding dosage and lifestyle modifications, including diet and physical activity. Common side effects may include mild gastrointestinal disturbances or headache, but it is generally well tolerated. Regular monitoring of blood glucose levels and renal function is recommended during treatment with Galvus OD 100mg Tablet MR to ensure safety and efficacy.